Our latest articles
Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
US Pdufa decisions loom for Apellis and Travere, while Menarini and Lilly got their approval firsts already.
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
The group continues its niche-targeting strategy with abelacimab’s latest pivotal trial.
A pivotal trial is in the works, but can the group succeed where other VEGF gene therapies have failed?
A pivotal study of Keytruda’s SC formulation is about to read out, but Roche could get to market first.
Medtech venture funding started strongly in 2022, but a slump in the fourth quarter could give rise to concern.
The biggest surprise is that there were a handful of risers despite the widespread market turmoil.
The Japanese company keeps the licensing fires burning with a $400m deal for Hutchmed’s fruquintinib.